课题基金 / 基金详情

Stereospecific Suzuki-Miyaura Csp3-Csp2 Cross-Coupling of Saturated Heterocyclic Boronates: Programmable Exploration of 3-D Space

Stereospecific Suzuki-Miyaura Csp3-Csp2 Cross-Coupling of Saturated Heterocyclic Boronates: Programmable Exploration of 3-D Space
饱和杂环硼酸酯的立体特异性 Suzuki-Miyaura Csp3-Csp2 交叉偶联:3D 空间的可编程探索
批准号:
2602986
负责人:
金额:
$0.0万
依托单位:
依托单位国家:
英国
项目类别:
Studentship
财政年份:
2021
资助国家:
英国
项目状态:
未结题
起止时间:
2021 至 --

项目摘要

项目成果

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Cyclic oxygen- and nitrogen-containing compounds (ring compounds that contain a series of carbon atoms and an oxygen or nitrogen atom) are very common structural units in a wide range of commercial pharmaceuticals. There is a growing interest for medicinal chemists in the pharmaceutical industry to work on chiral drug structures. Chiral molecules are compounds which exist in mirror image forms (just like our hands) - drugs need to be prepared with one handedness (known as single enantiomers) as each enantiomer can have different biological properties. One of the most widely used processes in the pharmaceutical industry to synthesise drug molecules is the Suzuki-Miyaura cross-coupling reaction, the importance of which was recognised with the award of the 2010 Nobel Prize. However, the Suzuki-Miyaura reaction has not been used to directly prepare chiral drug motifs - there is currently no method for the general Suzuki-Miyaura cross-coupling of chiral saturated heterocyclic boronates with aryl halides. This project will deliver such a process to enable transformative and non-traditional disconnections, fundamentally changing the way that three-dimensional saturated nitrogen- and oxygen-containing heterocycles are constructed. Reaction discovery and optimisation of suitable catalytic protocols will be driven by automated high throughput experimentation, rich data analysis and rigorous mechanistic studies. The ubiquity of chiral cyclic molecules containing in FDA-approved drugs ensures that the process will be an enabling and transformative technology for drug discovery in the pharmaceutical industry. Finally, there will be an opportunity to use our new methodology in the optimisation of fragment hits against proteins of interest for the treatment of covid-19. There are three specific research objectives:(i) to carry out the optimisation of Suzuki-Miyaura cross-coupling reactions of saturated oxygen- and nitrogen-containing heterocycles using high throughput experimentation, rich data analysis and ligand design(ii) to explore the scope and limitations of Suzuki-Miyaura cross-coupling reactions of saturated oxygen- and nitrogen-containing heterocycles (variations will include different boronates and aryl halides), drawing on mechanistic findings, particularly steps critical to productive catalysis(iii) to apply the newly developed methodology to analogue and library synthesis including covid-19-related fragment hits
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
国内基金
海外基金
钯催化不对称Suzuki-Miyaura偶联反应研究
  • 批准号:
    22301095
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    30万元
  • 批准年份:
    2023
  • 负责人:
    林桃燕
  • 依托单位:
类钯超原子基催化剂的理性设计及其催化Suzuki-Miyaura反应机理的理论研究
  • 批准号:
    22373016
  • 项目类别:
    面上项目
  • 资助金额:
    50万元
  • 批准年份:
    2023
  • 负责人:
    孙伟明
  • 依托单位:
钯催化的Suzuki/Heck串联反应制备多环芳烃和共轭梯形聚合物
  • 批准号:
    22371064
  • 项目类别:
    面上项目
  • 资助金额:
    50万元
  • 批准年份:
    2023
  • 负责人:
    武永刚
  • 依托单位:
配体设计在铜催化不对称自由基Suzuki C(sp3)–C交叉偶联反应的应用
  • 批准号:
    22371112
  • 项目类别:
    面上项目
  • 资助金额:
    50万元
  • 批准年份:
    2023
  • 负责人:
    李忠良
  • 依托单位: